Fig. 1 · Structure

Documents & Downloads

SP2509 (HCI-2509)

Cat. No. A14443 CAS 1423715-09-6

LSD1 inhibitor

SP2509 is a novel histone demethylase LSD1 (KDM1A) antagonist with IC50 of 13 nM; no inhibition on MAO-A and MAO-B.

In Stock

Publications for SP2509

1 publication citing this product

  1. Ziliang Yu, .et al. , Immunol Res, 2024, May 9 PMID: 38722530

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

SP2509 (HCI2509) has been investigated as an LSD1 antagonist. An independent recombinant-enzyme comparison measured an HTRF IC50 of 2.48 ± 1.21 μM. In MV(4;11) cells, the same study detected no LSD1 target engagement after 24 h at 2–2000 nM. These findings support caution when attributing a cellular response solely to LSD1 inhibition. [1]

In A673 Ewing sarcoma cells, SP-2509 reduced the thermal stability of several mitochondrial proteins, including UQCRFS1, and later depleted UQCRFS1 and NDUFS1. These findings identify mitochondrial protein effects relevant to interpreting compound activity; thermal-shift changes alone do not establish direct binding. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
LSD1 13 nM

Cellular Effect

Cell Line Activity Value Description Reference
A2780 IC50 0.77 μM Antiproliferative activity against human A2780 cells over-expressing LSD1 assessed as reduction in cell viability measured after 96 hrs by MTT assay [PMID: 27524309]
A2780 IC50 2.14 μM Antiproliferative activity against human A2780 cells over-expressing LSD1 assessed as reduction in cell viability measured after 72 hrs by MTT assay [PMID: 27524309]
A549 IC50 0.83 μM Antiproliferative activity against human A549 cells over-expressing LSD1 assessed as reduction in cell viability measured after 96 hrs by MTT assay [PMID: 27524309]
A549 IC50 2.69 μM Antiproliferative activity against human A549 cells over-expressing LSD1 assessed as reduction in cell viability measured after 72 hrs by MTT assay [PMID: 27524309]
AGS IC50 6.19 μM Antiproliferative activity against human AGS cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay [PMID: 33957387]
AN3-CA IC50 0.356 μM Growth inhibition of human AN3CA cells after 96 hrs by ATPlite luminescence assay [PMID: 24237195]
BGC-823 IC50 8.08 μM Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo assay [PMID: 33957387]
BT-20 IC50 0.489 μM Growth inhibition of human BT20 cells after 96 hrs by ATPlite luminescence assay [PMID: 24237195]
BT-549 IC50 1.01 μM Growth inhibition of human BT549 cells after 96 hrs by ATPlite luminescence assay [PMID: 24237195]
DU-145 IC50 0.62 μM Antiproliferative activity against human DU145 cells over-expressing LSD1 assessed as reduction in cell viability measured after 96 hrs by MTT assay [PMID: 27524309]
DU-145 IC50 13.08 μM Antiproliferative activity against human DU145 cells over-expressing LSD1 assessed as reduction in cell viability measured after 72 hrs by MTT assay [PMID: 27524309]
HCT-116 IC50 0.33 μM Antiproliferative activity against human HCT116 cells over-expressing LSD1 assessed as reduction in cell viability measured after 96 hrs by MTT assay [PMID: 27524309]
HCT-116 IC50 0.614 μM Growth inhibition of human HCT116 cells after 96 hrs by ATPlite luminescence assay [PMID: 24237195]
HCT-116 IC50 0.65 μM Antiproliferative activity against human HCT116 cells over-expressing LSD1 assessed as reduction in cell viability measured after 72 hrs by MTT assay [PMID: 27524309]
Hs-578T IC50 1.7 μM Growth inhibition of human Hs 578T cells after 96 hrs by ATPlite luminescence assay [PMID: 24237195]
HT-29 IC50 0.429 μM Growth inhibition of human HT-29 cells after 96 hrs by ATPlite luminescence assay [PMID: 24237195]
MCF7 IC50 0.19 μM Antiproliferative activity against human MCF7 cells over-expressing LSD1 assessed as reduction in cell viability measured after 96 hrs by MTT assay [PMID: 27524309]
MCF7 IC50 0.44 μM Antiproliferative activity against human MCF7 cells over-expressing LSD1 assessed as reduction in cell viability measured after 72 hrs by MTT assay [PMID: 27524309]
MCF7 IC50 0.62 μM Antiproliferative activity against human MCF7 cells after 48 to 72 hrs by MTT assay [PMID: 29754076]

19 records · Scroll to view more

In Vitro Studies

HCI2509 at 2 μM for 48 h increased TUNEL staining in A673 cells relative to vehicle, consistent with apoptosis-associated DNA fragmentation. This cellular phenotype does not establish a target-specific mechanism. [3]

Recombinant LSD1 inhibition in an HTRF assay

Biochemical assay · Human recombinant LSD1; biotinylated monomethyl H3(1–21)K4 substrate [1]

SP-2509 inhibited LSD1 with a micromolar IC50 in this assay. The figure reports 2.48 ± 1.21 μM; the Results text rounds this to 2.5 μM. This is an assay endpoint, not a treatment dose.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of recombinant LSD1 catalytic activityIC50 2.48 ± 1.21 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Serial compound dilutions; study capped SP-2509 testing at 30 μM because of solubility concerns
Exposure duration
15 min preincubation on ice; 1 h enzyme reaction at 25 °C; 1 h detection at 25 °C
Method
HTRF readout; 0.45 nM recombinant LSD1; substrate at Km; 10 μM FAD
Vehicle
0.5% DMSO
Reported limits
Exact serial dilution range is not specified in the HTRF subsection.
Methods and source locations

Compound reported in the paper: SP-2509 (HCI2509); Compound label in the paper: SP-2509

Evidence applies to the named research compound and stated model, without salt conversion or supplier-lot equivalence.

Figure 2A,C (SP-2509 row) and caption; Catalytic Inhibitory Potency and Selectivity; Methods: LSD1 HTRF Assay

Inhibition of recombinant LSD1 catalytic activity: Figure 2 reports mean ± SD; N = 2, n = 2 or 3. HTRF methods specify triplicate compound dilutions. Nonlinear four-parameter fit; no-inhibitor activity control and no-enzyme background; highest-dose detection-interference check. — Figure 2A,C (SP-2509 row) and caption; Catalytic Inhibitory Potency and Selectivity; Methods: LSD1 HTRF Assay

LSD1 target engagement in MV(4;11) cells

Cell-based study · Human MV(4;11) acute myeloid leukemia cells [1]

The authors detected no LSD1 target engagement for SP-2509 under the tested conditions. Active comparator inhibitors, including reversible pulrodemstat, produced detectable engagement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LSD1 target engagement relative to vehicleQualitative result No LSD1 target engagement observed for SP-2509[1]

Literature-Reported Treatment Conditions

Treatment concentration
2000, 200, 20 and 2 nM
Exposure duration
24 h
Method
Biotinylated LSD1 chemoprobe followed by free/total LSD1 luminescent ELISAs
Vehicle
Vehicle control; composition not specified in the target-engagement subsection
Reported limits
No exact target-engagement percentages are transcribed from bars.
Methods and source locations

Compound reported in the paper: SP-2509 (HCI2509); Compound label in the paper: SP-2509

Evidence applies to the named research compound and stated model, without salt conversion or supplier-lot equivalence.

Figure 3B and caption; Results paragraph beginning To assess whether the impact on AML cell viability; Methods: Analysis of LSD1 Target Engagement; Discussion

LSD1 target engagement relative to vehicle: Figure 3B: N = 1, n = 3; mean ± SD; vehicle and active inhibitor comparators. Native extracts assayed with a covalent biotinylated probe. — Figure 3B and caption; Results paragraph beginning To assess whether the impact on AML cell viability; Methods: Analysis of LSD1 Target Engagement; Discussion

SP-2509 effects on mitochondrial protein stability

Cell-based study · Human A673 Ewing sarcoma cells [2]

SP-2509 reduced the thermal stability of UQCRFS1, LYRM7 and NDUFS1. UQCRFS1 destabilization was concentration dependent. Total UQCRFS1 and NDUFS1 were depleted at 24–48 h, whereas the heme-containing comparator CYC1 was not similarly depleted.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Thermal stability and abundance of mitochondrial proteinsQualitative result Reduced thermal stability; later depletion of UQCRFS1 and NDUFS1[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM for thermal-shift and total-protein experiments; 2–30,000 nM in the isothermal concentration series
Exposure duration
3 h for CETSA; 3, 24 and 48 h for total-protein immunoblots
Method
CETSA Western blot and tubulin-normalized total-protein immunoblot; isothermal CETSA at 48 °C
Vehicle
0.1% DMSO
Reported limits
Replication count for the Figure 2 immunoblots is not specified in its caption; exact stability shifts are not inferred.
Methods and source locations

Compound reported in the paper: SP-2509 (HCI2509); Compound label in the paper: SP-2509

Evidence applies to the named research compound and stated model, without salt conversion or supplier-lot equivalence.

Figure 2A,B,E,F and caption; Results: SP-2577/2509 Alters the Stability; SP-2509 Destabilizes UQCRFS1; SP-2509 Causes a Time-Dependent Depletion; Reagents; CETSA/isothermal CETSA/Western Blot methods

Thermal stability and abundance of mitochondrial proteins: Figure 2A,B,E,F viewed; tubulin normalization and CYC1 comparator. No exact band intensity is inferred. — Figure 2A,B,E,F and caption; Results: SP-2577/2509 Alters the Stability; SP-2509 Destabilizes UQCRFS1; SP-2509 Causes a Time-Dependent Depletion; Reagents; CETSA/isothermal CETSA/Western Blot methods

Apoptosis-associated DNA fragmentation in A673 cells

Cell-based study · Human A673 Ewing sarcoma cells [3]

HCI2509 increased TUNEL staining relative to vehicle in A673 cells, supporting apoptosis-associated DNA fragmentation under these conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TUNEL-positive stainingQualitative result Increased TUNEL staining versus vehicle[3]

Literature-Reported Treatment Conditions

Treatment concentration
2 μM
Exposure duration
48 h
Method
DeadEnd Colorimetric TUNEL assay
Vehicle
0.3% DMSO
Reported limits
The TUNEL panel is qualitative; no percentage of positive cells or replicate count is specified in its caption.
Methods and source locations

Compound reported in the paper: SP-2509 (HCI2509); Compound label in the paper: HCI2509

Evidence applies to the named research compound and stated model, without salt conversion or supplier-lot equivalence.

Figure 3D,E and caption; Methods: In vitro apoptosis assays; Results paragraph discussing TUNEL staining and caspase activation

TUNEL-positive staining: Figure 3D viewed; negative control lacks labeling, positive control is DNase treatment with labeling. — Figure 3D,E and caption; Methods: In vitro apoptosis assays; Results paragraph discussing TUNEL staining and caspase activation

In Vivo Studies

In an A673 xenograft study, daily intraperitoneal HCI2509 at 30 mg/kg delayed tumor growth and improved tumor-endpoint survival versus vehicle. The survival analysis used a 2 cm³ tumor-size euthanasia threshold. These findings are specific to this preclinical model. [3]

HCI2509 in an A673 xenograft model

Animal study · Nude mice bearing subcutaneous A673 Ewing sarcoma xenografts [3]

Daily HCI2509 delayed tumor growth and improved the tumor-endpoint survival curve versus vehicle in the A673 model. Mice were euthanized when tumors reached 2 cm³, so this survival endpoint includes a tumor-size stopping rule.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor growth and tumor-endpoint survival versus vehicleReported statistical comparison Tumor growth: p < 0.0001; survival: p = 1.09E−2[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Daily
Treatment course
Started on day 7 after engraftment confirmation; fixed course not established from acquired main text
Vehicle
Formulation not established from acquired main text
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
HCI2509 monotherapy versus vehicle
30 mg/kg
Vehicle-treated A673 xenograft mice; n = 10 per groupDelayed tumor growth and improved tumor-endpoint survival; euthanasia threshold 2 cm³[3]
HCI2509 monotherapy versus vehicle
Model: Nude mice bearing subcutaneous A673 Ewing sarcoma xenografts
Reported limits: Vehicle formulation and fixed treatment-course length not established; no dosing recommendation inferred.
Methods and source locations

Compound reported in the paper: SP-2509 (HCI2509); Compound label in the paper: HCI2509

Evidence applies to the named research compound and stated model, without salt conversion or supplier-lot equivalence.

Figure 5A,C and caption; Methods: In vivo Studies—Xenografts; Results: HCI2509 as a single agent significantly reduces tumor growth in vivo

Tumor growth and tumor-endpoint survival versus vehicle: Figure 5A,C viewed: n = 10 mice per group; tumor growth compared by two-way ANOVA, survival by log-rank (Mantel–Cox) test. No numerical tumor-volume reduction inferred. — Figure 5A,C and caption; Methods: In vivo Studies—Xenografts; Results: HCI2509 as a single agent significantly reduces tumor growth in vivo

HCI2509 monotherapy versus vehicle · Figure 5A,C and caption; Methods: In vivo Studies—Xenografts; Results: HCI2509 as a single agent significantly reduces tumor growth in vivo

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor, Antagonist
CAS Number 1423715-09-6
Applications LSD1 inhibitor
Formula C19H20ClN3O5S
Molecular Weight 437.9
Synonyms HCI-2509
SMILES
CC(=C1C=C(C=CC1=O)Cl)NNC(=O)C2=CC(=CC=C2)S(=O)(=O)N3CCOCC3

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 36 mg/mL (82.2 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
10% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Sacilotto N, Dessanti P, Lufino MMP, et al. Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology. ACS Pharmacol Transl Sci (2021). PMID: 34927013 DOI: 10.1021/acsptsci.1c00223 Source material
  2. [2] Sherman JW, Rask GC, Xiong B, et al. N′-(1-Phenylethylidene)benzohydrazide Cytotoxicity Is Lysine-Specific Demethylase 1 Independent and Linked to Iron–Sulfur Cluster Disruption in Ewing Sarcoma. ACS Pharmacol Transl Sci (2025). PMID: 41262575 DOI: 10.1021/acsptsci.5c00447 Source material
  3. [3] Sankar S, Theisen ER, Bearss J, et al. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res (2014). PMID: 24963049 DOI: 10.1158/1078-0432.ccr-14-0072 Source material

Publications

1 publication citing this product

  1. Ziliang Yu, .et al. , Immunol Res, 2024, May 9 PMID: 38722530

Added to your cart

View Cart Checkout
Loading...